勘误：使用马尔可夫模型评估维多珠单抗在日本溃疡性结肠炎治疗模式中的最佳位置。
Erratum: Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling.
作者信息
Uda Akihito, Eto Yuki, Li Yuxin, Matsuda Hiroyuki, Demiya Sven, Watanabe Tomoyuki, Ota Mihoko, Iwakiri Ryuichi, Igarashi Ataru
出版信息
Crohns Colitis 360. 2020 May 30;2(2):otaa036. doi: 10.1093/crocol/otaa036. eCollection 2020 Apr.
Abstract
[This corrects the article DOI: 10.1093/crocol/otaa017.].
摘要
[本文更正了文章的数字对象标识符：10.1093/crocol/otaa017。]
相似文献
1
Erratum: Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling.勘误：使用马尔可夫模型评估维多珠单抗在日本溃疡性结肠炎治疗模式中的最佳位置。
Crohns Colitis 360. 2020 May 30;2(2):otaa036. doi: 10.1093/crocol/otaa036. eCollection 2020 Apr.
2
Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling.使用马尔可夫模型评估维多珠单抗在日本溃疡性结肠炎治疗模式中的最佳位置。
Crohns Colitis 360. 2020 Mar 18;2(2):otaa017. doi: 10.1093/crocol/otaa017. eCollection 2020 Apr.
3
Correction to: Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.对《溃疡性结肠炎和克罗恩病中皮下注射维多珠单抗的实际应用场景实用入门指南：VISIBLE研究的事后分析》的勘误
Crohns Colitis 360. 2023 Nov 24;5(4):otad071. doi: 10.1093/crocol/otad071. eCollection 2023 Oct.
4
Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model.评估维得利珠单抗治疗溃疡性结肠炎的最佳位置：模拟模型。
Inflamm Bowel Dis. 2018 Jan 18;24(2):286-295. doi: 10.1093/ibd/izx045.
5
Erratum: Clinical Outcome Assessments in Pediatric Patients With Ulcerative Colitis and Crohn's Disease Receiving Biologics: A Retrospective Cohort Study.勘误：接受生物制剂治疗的溃疡性结肠炎和克罗恩病儿科患者的临床结局评估：一项回顾性队列研究。
Crohns Colitis 360. 2022 Dec 9;4(4):otac049. doi: 10.1093/crocol/otac049. eCollection 2022 Oct.
6
A Phase 1, Multiple-Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis.一项评估维得利珠单抗治疗日本溃疡性结肠炎患者的 1 期、多剂量研究。
J Clin Pharmacol. 2019 Feb;59(2):271-279. doi: 10.1002/jcph.1307. Epub 2018 Sep 7.
7
Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.识别维得利珠单抗在治疗溃疡性结肠炎的现有生物药物中的最具成本效益的位置。
J Crohns Colitis. 2020 Jun 19;14(5):575-587. doi: 10.1093/ecco-jcc/jjz212.
8
Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.更正：维多珠单抗治疗日本溃疡性结肠炎患者：一项3期、随机、双盲、安慰剂对照研究。
PLoS One. 2019 Apr 11;14(4):e0215491. doi: 10.1371/journal.pone.0215491. eCollection 2019.
9
Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center.三级转诊中心维多珠单抗治疗溃疡性结肠炎和克罗恩病的真实世界疗效
Dig Dis. 2019;37(1):33-44. doi: 10.1159/000492322. Epub 2018 Aug 22.
10
Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada.加拿大皮下注射维多珠单抗用于溃疡性结肠炎维持治疗的成本效益
Pharmacoecon Open. 2022 Jul;6(4):519-537. doi: 10.1007/s41669-022-00331-9. Epub 2022 Apr 26.
Zotero 插件